|
KR100704059B1
(ko)
|
1997-06-12 |
2007-04-05 |
롱프랑 로라 리미티드 |
이미다졸릴-사이클릭 아세탈
|
|
CA2904794C
(en)
|
2013-03-15 |
2021-11-23 |
Peter Walter |
Modulators of the eif2alpha pathway
|
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TW201808888A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TW201808903A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
US20190298705A1
(en)
|
2016-06-08 |
2019-10-03 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical Compounds
|
|
KR20190015492A
(ko)
|
2016-06-08 |
2019-02-13 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
화학적 화합물
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
BR112020000122A2
(pt)
|
2017-07-03 |
2020-07-07 |
Glaxosmithkline Intellectual Property Development Limited |
derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças
|
|
EP3649108A1
(en)
|
2017-07-03 |
2020-05-13 |
GlaxoSmithKline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
CA3071024A1
(en)
*
|
2017-08-09 |
2019-02-14 |
Denali Therapeutics Inc. |
Compounds, compositions and methods
|
|
CN111201245B
(zh)
|
2017-09-01 |
2024-04-05 |
戴纳立制药公司 |
化合物、组合物和方法
|
|
WO2019090090A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
WO2019090074A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
AU2018358157B2
(en)
|
2017-11-02 |
2023-03-09 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
JP2021501781A
(ja)
|
2017-11-02 |
2021-01-21 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
|
CA3080808A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
WO2019090088A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
CN111757739A
(zh)
|
2017-12-13 |
2020-10-09 |
普拉西斯生物技术有限责任公司 |
整合应激反应路径抑制剂
|
|
WO2019183589A1
(en)
|
2018-03-23 |
2019-09-26 |
Denali Therapeutics Inc. |
Modulators of eukaryotic initiation factor 2
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
AU2019282253A1
(en)
|
2018-06-05 |
2020-11-26 |
Altos Labs, Inc. |
Inhibitors of integrated stress response pathway
|
|
WO2020012339A1
(en)
|
2018-07-09 |
2020-01-16 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
TW202545902A
(zh)
|
2018-10-11 |
2025-12-01 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
|
EP3924341A4
(en)
|
2019-02-13 |
2022-11-02 |
Denali Therapeutics Inc. |
Compounds, compositions and methods
|
|
SG11202108552QA
(en)
|
2019-02-13 |
2021-09-29 |
Denali Therapeutics Inc |
Compounds, compositions and methods
|
|
CA3130511A1
(en)
|
2019-02-25 |
2020-09-03 |
Praxis Biotech LLC |
Inhibitors of integrated stress response pathway
|
|
WO2020181247A1
(en)
|
2019-03-06 |
2020-09-10 |
Denali Therapeutics Inc. |
Compounds, compositions and methods
|
|
EP3959198A1
(en)
|
2019-04-23 |
2022-03-02 |
Evotec International GmbH |
Modulators of the integrated stress response pathway
|
|
MX2021012904A
(es)
|
2019-04-23 |
2022-01-18 |
Evotec Int Gmbh |
Moduladores de la via de respuesta al estres integrada.
|
|
SG11202111970WA
(en)
|
2019-04-30 |
2021-11-29 |
Calico Life Sciences Llc |
Substituted cyclolakyls as modulators of the integrated stress pathway
|
|
PE20220572A1
(es)
|
2019-04-30 |
2022-04-20 |
Calico Life Sciences Llc |
Moduladores de la via integrada del estres
|
|
WO2020252207A1
(en)
|
2019-06-12 |
2020-12-17 |
Praxis Biotech LLC |
Modulators of integrated stress response pathway
|
|
WO2020252205A1
(en)
|
2019-06-12 |
2020-12-17 |
Praxis Biotech LLC |
Inhibitors of integrated stress response pathway
|
|
JP7699595B2
(ja)
|
2020-01-28 |
2025-06-27 |
エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
統合的ストレス応答経路の調節因子
|
|
EP4232153A1
(en)
|
2020-10-22 |
2023-08-30 |
Evotec International GmbH |
Modulators of the integrated stress response pathway
|
|
EP4232447A1
(en)
|
2020-10-22 |
2023-08-30 |
Evotec International GmbH |
Modulators of the integrated stress response pathway
|
|
RS66455B1
(sr)
|
2020-10-22 |
2025-02-28 |
Evotec Int Gmbh |
Modulatori puta integrisanog odgovora na stres
|